grade
pharmaceutical primary standard
API family
diazoxide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1
InChI
1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)
InChI key
GDLBFKVLRPITMI-UHFFFAOYSA-N
Gene Information
human ... KCNJ11(3767), KCNJ8(3764)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Diazoxide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 二氮嗪
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
Bernard Pirotte et al.
Journal of medicinal chemistry, 56(8), 3247-3256 (2013-03-23)
The synthesis of diversely substituted 3-alkyl/aralkyl/arylamino-1,4,2-benzodithiazine 1,1-dioxides and 3-alkylaminopyrido[4,3-e]-1,4,2-dithiazine 1,1-dioxides is described. Their biological activities on pancreatic β-cells and on smooth muscle cells were compared to those of the reference ATP-sensitive potassium channel (KATP channel) openers diazoxide and 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide.
William A Coetzee
Pharmacology & therapeutics, 140(2), 167-175 (2013-06-25)
Diazoxide has been identified over the past 50years to have a number of physiological effects, including lowering the blood pressure and rectifying hypoglycemia. Today it is used clinically to treat these conditions. More recently, another important mode of action emerged:
R M Pearson
Clinical pharmacokinetics, 2(3), 198-204 (1977-05-01)
Diazoxide is given by rapid intravenous injection for the urgent reduction of high blood pressure in patients with all grades of renal function. Oral diazoxide produces less consistent effects. Protein binding of diazoxide is reduced in renal failure and this
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| D0950000 | 04061833558249 |